Paul S. Aisen M.D. is the Director of the Alzheimer's Disease Cooperative Study (ADCS) and Professor in the Department of Neurosciences at UCSD. He has been conducting therapeutic research on Alzheimer's disease for the past two decades. Dr. Aisen joined the faculty at Georgetown University in 1999 as Professor in the Departments of Neurology and Medicine and that year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer's disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers of AD and designed and directed multicenter therapeutic trials. He became Vice Chair of the Department of Neurology at Georgetown in 2004. Following the tragic death of ADCS founder Leon Thal, M.D. in early 2007, Dr. Aisen relocated to UCSD to assume the position of Director of the ADCS and Professor of Neurosciences.
Jeffrey Cummings, MD, ScD, is Director of Cleveland Clinic Lou Ruvo Center for Brain Health and the Camille and Larry Ruvo Chair for Brain Health. Dr. Cummings' research and leadership in the field of Alzheimer's disease have been recognized with many awards, including the Henderson Award of the American Geriatrics Society, the Research Award of the John Douglas French Alzheimer's Research Foundation, and the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association.Dr. Cummings is the author of the Neuropsychiatric Inventory (NPI), the most commonly used tool for characterizing behavioral disturbances in dementia syndromes and for measuring the effect of therapies on neuropsychiatric symptoms in Alzheimer's disease and other dementias.
Serge Gauthier, MD, FRCPC - Dr. Gauthier is currently Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital.
He did his medical training at Université de Montréal, Neurology training at McGill University, Research Fellowship at Prof. Theodore L. Sourkes laboratory, Allen Memorial Institute, Montreal. Clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976-1986), Director of the McGill Centre for Studies in Aging (1886-1996), Senior Scientist of the CIHR-Rx&D program (1997-2007).
Contributions to research include design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors, muscarinic agonists, and agents possibly modifying progression for Alzheimer’s disease and vascular dementia. Special interests include consensus approach to the management of dementia in different stages, the ethics of research involving persons with dementia, and primary prevention strategies against cognitive decline and dementia.
David M. Holtzman, is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, and a member of the Hope Center for Neurological Disorders at the Washington University School of Medicine in St. Louis, MO – USA
His major interest is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS particularly as these mechanisms may relate to Alzheimer's disease (AD) and injury to the developing brain.
William C. Mobley is a Distinguished Professor and Chair of the Department of Neurosciences at UCSD. He also serves as Executive Director of UCSD's Down Syndrome Center for Research and Treatment.
Dr. Mobley has a distinguished record of academic achievement and is considered one of the most outstanding academic neurologists in the US. He has an international reputation for his research on degenerative disease of the central nervous system as well as being a leader in translational medicine, bridging clinical and basic science in various areas.
Ronald C. Petersen, MD, PhD is the Director of the Mayo Alzheimer's Disease Research Center and has an interest in clinical research involving aging, mild cognitive impairment, dementia, Alzheimer's Disease, and neuroimaging. The Mayo Alzheimer's Disease Research Center is part of a network of 28 centers around the country sponsored by the National Institute on Aging. This center operates in Rochester, MN and Jacksonville, FL. In addition, Dr. Petersen has a National Institute on Aging funded registry on aging and dementia in Rochester. This is a longitudinal project on clinical, epidemiological, genetic, biomarker, imaging, and neuropathological aspects of aging and very early cognitive impairment. His team is developing models for predicting a subsequent cognitive impairment in normal elderly persons. A great deal of his work has focused on mild cognitive impairment as an intermediate stage between normal aging and Alzheimer's disease. Recently, he has begun a project funded by the Mayo Foundation investigating various aspects of successful cognitive aging in the community. He also studies non-Alzheimer's disease dementias such as frontotemporal dementia, dementia with Lewy bodies and vascular dementia.
Dr. Eric Reiman is chief executive officer of Banner Research, executive director of Banner Alzheimer's Institute, clinical director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), professor of psychiatry at the University of Arizona, and director of the Arizona Alzheimer's Consortium. His research interests include brain imaging, genomics and their application to the study of normal and abnormal human behaviors; the early detection, tracking and study of Alzheimer's disease; and the accelerated evaluation of presymptomatic Alzheimer's disease treatments.
Dr. Reiman is internationally recognized for his contributions to the fields of brain imaging, the behavioral neurosciences and the presymptomatic study of Alzheimer's disease.
ANT Congrès - 154 avenue de Lodève - 34070 Montpellier - France
E-mail : email@example.com
Tel : + 33 (0) 6 85 54 70 98
Fax : + 33 (0)4 67 10 92 23